Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Sees Large Increase in Short Interest

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 55,100 shares, a growth of 2,523.8% from the January 15th total of 2,100 shares. Based on an average daily volume of 171,000 shares, the days-to-cover ratio is presently 0.3 days.

Enzon Pharmaceuticals Price Performance

Enzon Pharmaceuticals stock opened at $0.15 on Thursday. Enzon Pharmaceuticals has a 12 month low of $0.06 and a 12 month high of $0.24. The business has a 50 day simple moving average of $0.15 and a 200-day simple moving average of $0.13. The stock has a market capitalization of $11.13 million, a PE ratio of 15.02 and a beta of 0.26.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.